| |
|
 |
|
MODERN RHEUMATOLOGY Vol.13 No.4
>MR13-4
|
| An overview on systemic lupus erythematosus pregnancy |
|
| Wei Zhang1 and Shun-le Chen1 |
| (1) Department of Rheumatology, Renji Hospital, Shanghai Institute for Rheumatology, Shanghai Second Medical University, Mid ShanDong Rd., 145, Shanghai, 200001, PR China |
| |
Full Text
> Click Here （member's only） |
| |
| Abstract |
| A systemic lupus erythematosus (SLE) pregnancy is no longer regarded as unacceptable, with an early diagnosis, a mild disease condition, and good interdisciplinary collaboration ensuring intense surveillance of pregnant SLE patients. The key point is a sufficiently long period of disease quiescence before conception. A low dose of prednisone is preferable during pregnancy. Nevertheless, 20% of disease flare-up still happens interpartum or postpartum, even in such well-planned pregnancies, although usually with only mild severity. Pregnancy during an active disease stage, especially active nephritis, should always be avoided. Substantial renal function damage may occur, and there is a relatively high prevalence of preeclampsia, which may further compromise the mother as well as the fetus. It is well documented that antiphospholipid syndrome and antiphospholipid antibodies are strongly associated with fetal wastage. Low-dose aspirin or heparin is indicated for a favorable fetal outcome. Women with positive anti-SSA and/or anti-SSB should be aware of the danger of congenital heart block in their infants. Cytotoxic drugs applied in the early stage of pregnancy are dangerous to the fetus. A rather long-term follow-up is required to make a precise evaluation of the maternal SLE influence on the offspring. |
| |
| Key words |
Fetus - Medication - Pregnancy - Risk - Systemic lupus erythematosus (SLE) |
|
| |
| 一覧に戻る |
|
|
